semaglutide and the risk of non arteritic ischemic optic neuropathy a systematic review and certainty of evidence meta analysis

Original title: “Semaglutide and the Risk of Non-Arteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.”

new onset nonarteritic anterior ischemic optic neuropathy and initiators of semaglutide in us veterans with type 2 diabetes

Original title: “New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes.”

A milestone moment for longevity as Life Biosciences gets green light to progress cellular rejuvenation trial in eye disease. The Nobel prize-winning discovery sparked a global race to harness the approach therapeutically, and today marks a historic milestone in that journey with the news that the FDA has given the go-ahead for the first ever human trial of a partial epigenetic reprogramming therapy. The FDA’s decision clears an investigational new drug application for Life Bioscience’s ER-100, a gene therapy designed to rejuvenate damaged retinal cells in people with serious, age-related eye diseases. The Boston-based biotech co-founded by Harvard professor Dr David Sinclair, who showed in 2020 that a partial epigenetic reprogramming treatment restored vision in blind mice, is now preparing to commence a Phase 1 first-in-human study to show its therapy can be delivered safely in patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). More broadly, the company views the trial as a test case for an entire therapeutic platform. “Demonstrating that partial epigenetic reprogramming can be deployed in humans opens the door to applying the same approach to other age-related diseases and organ system,” said Rosenzweig-Lipson. While the eye is seen as an ideal starting point because it is accessible and allows for localized treatment, Life Bio is already exploring other potential applications for its technology. By excluding c-Myc, a factor associated with uncontrolled growth, the strategy is intended to lower the risk of tumors that has historically concerned regulators and clinicians. From a safety perspective, Rosenzweig-Lipson told us that the company’s preclinical studies in non-human primates demonstrated that ER-100 was well tolerated, with no systemic toxicities. “The therapy also uses a doxycycline-inducible system, giving us precise control over when the genes are active and allowing treatment to be paused or stopped if needed,” she added. This shift from aspiration to evidence-based clinical development is helping move the whole field forward.” ... Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Original title: “FDA clears first human trial of epigenetic reprogramming therapy”